Accelerate Diagnostics, Inc. is an in vitro diagnostics company focusing on providing solutions for antibiotic resistance and sepsis.

According to the law firm press release, the lawsuit alleges Defendants misrepresented and/or failed to disclose to investors that Accelerate Diagnostics’ main product, the ID/AST system, formally known as the BACcel system, requires a positive blood culture to diagnose pathogens in a blood sample. When the truth was revealed to investors, the price of Accelerate Diagnostics securities fell, damaging investors.

On January 28, 2016, the Court issued an Order granting Defendants' Motion to Dismiss and dismissing this action with prejudice. On February 26, Plaintiff filed a Notice of Appeal of this decision. On September 13, 2017, the Appeal was dismissed.